Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,428.38 3.53 0.02%
S&P 500 1,864.02 1.71 0.09%
NASDAQ 4,095.94 9.71 0.24%
Ticker Volume Price Price Delta
STOXX 50 3,151.54 12.28 0.39%
FTSE 100 6,622.26 38.09 0.58%
DAX 9,396.65 78.83 0.85%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

Delcath Systems, Inc : DELCATH EXPANDS PROGRAM TO INCREASE EFFICIENCIES AND REDUCE CASH UTILIZATION



 Delcath Systems, Inc : DELCATH EXPANDS PROGRAM TO INCREASE EFFICIENCIES AND
                           REDUCE CASH UTILIZATION

 Jennifer Simpson, PhD, MSN, CRNP Named Executive Vice President, Global Head
                            of Business Operations

NEW YORK, NY  - April 8,  2013 -  Delcath Systems, Inc.  (NASDAQ: DCTH)  today 
announced that  as  a part  of  the  Company's continued  effort  to  increase 
efficiencies and  reduce  cash  utilization,  it  has  implemented  a  program 
designed to decrease the Company's  2013 quarterly operating cash  utilization 
to between $9 million and $10  million from the previously communicated  range 
of $9 million to $12 million, beginning  in the second half of 2013.  Combined 
with the Company's approximate $42 million  cash position  at March 31,  2013, 
the program  is expected to provide  Delcath with sufficient resources for  at 
least the next 12 months as the Company pursues three key objectives: U.S. FDA
approval for Melblez^TM Kit  (Melblez (melphalan) for  Injection for use  with 
the  Delcath   Hepatic  Delivery   System),  European   commercialization   of 
 CHEMOSAT^® Hepatic Delivery System  for melphalan hydrochloride, and  ongoing 
clinical development focused on label expansion.

To achieve the program's goals,  Delcath has expanded workforce  restructuring 
actions which have reduced the Company's workforce by approximately 21 percent
this year.  In addition, the actions announced today are expected to  continue 
the Company's reduction  of expenses  incurred with  outside consultants.   To 
increase efficiency,  the  Company  will  be  changing  the   address  of  its 
headquarters to its Queensbury,  NY facilities, and  is pursuing a  relocation 
project to  move  its  New York  City  operations  to a  more  cost  effective 
satellite office in New Jersey.

The expanded efficiency  program includes the  promotion of Jennifer  Simpson, 
Ph.D., MSN, CRNP to  the newly created position  of Executive Vice  President, 
Global Head of Business Operations, effective immediately. Dr. Simpson  joined 
Delcath in March 2012 as Executive Vice President, Global Marketing,  bringing 
an extensive background  in pharmaceutical and  oncology marketing,  including 
responsibility for global product development  in the oncology sector. In  her 
new  capacity,  Dr.  Simpson  will  have  responsibility  for  global   sales, 
marketing, regulatory,  quality,  clinical development,  and  medical  affairs 
activities.  The efficiency  program includes  the elimination  of two  senior 
level positions;  global  sales,  the  responsibilities  of  which  have  been 
absorbed by  Dr. Simpson  and business  development, the  responsibilities  of 
which have been absorbed by Delcath's President & CEO, Eamonn Hobbs, and  CFO, 
Graham Miao.  

"The  expansion   of   these   programs  will   significantly   increase   our 
organizational efficiencies, reduce  expected cash burn  in 2013, and  provide 
the necessary resources to fund our three key strategic priorities," said  Mr. 
Hobbs.  "Our team is highly focused on preparations for our May 2^nd Oncologic
Drugs Advisory Committee panel meeting, as  well as our ongoing dialogue  with 
the FDA regarding their review of our NDA submission."

About Delcath Systems

Delcath Systems, Inc. is a specialty pharmaceutical and medical device company
focused on  oncology. Our  proprietary  drug/device combination  product,  the 
Delcath  Hepatic  Delivery  System,  is  designed  to  administer  high   dose 
chemotherapy and other therapeutic agents to diseased organs or regions of the
body, while controlling the systemic  exposure of those agents. The  Company's 
initial focus is on the treatment of primary and metastatic liver cancers.  In 
2010, Delcath  announced  that  its  randomized Phase  3  clinical  trial  for 
patients with metastatic melanoma in  the liver had successfully achieved  the 
study's primary endpoint  of extended hepatic  progression-free survival.  The 
Company also completed a multi-arm Phase 2 trial to treat other liver cancers.
Outside of the United  States, our proprietary product  to deliver and  filter 
melphalan hydrochloride  is  marketed under  the  trade name  Delcath  Hepatic 
CHEMOSAT® Delivery  System  (CHEMOSAT  Delivery  System  for  Melphalan.)  The 
Company obtained  authorization to  affix a  CE Mark  for the  Generation  Two 
CHEMOSAT Delivery System for Melphalan in April 2012.  The right to affix  the 
CE mark allows the Company to market and sell the CHEMOSAT Delivery System for
Melphalan in  Europe.  In October  2012,  the  Company satisfied  all  of  the 
requirements to affix  the CE  Mark to  the Hepatic  CHEMOSAT Delivery  System 
device for intra-hepatic  arterial delivery and  extracorporeal filtration  of 
doxorubicin   hydrochloride   injection   (CHEMOSAT   Delivery   System    for 
Doxorubicin), providing a regulatory pathway for the CHEMOSAT Delivery  System 
for Doxorubicin for countries in  Asia that accept the  CE Marking as part  of 
their national regulatory requirements.  The Company has not yet received  FDA 
approval for commercial sale of its system in the United States. The Company's
NDA has been accepted for filing and substantive review by the FDA.  For  more 
information, please visit the Company's website at www.delcath.com.

Private Securities Litigation Reform  Act of 1995 provides  a safe harbor  for 
forward-looking statements made  by the Company  or on its  behalf. This  news 
release contains  forward-looking statements,  which  are subject  to  certain 
risks and uncertainties  that can  cause actual results  to differ  materially 
from those described. Factors that may cause such differences include, but are
not limited to, uncertainties  relating to: the outcome  of the ODAC  meeting, 
and the impact, if  any, of the advisory  panel's recommendation on the  FDA's 
decision regarding  the  Company's  new  drug  application  (NDA),  timing  of 
completion of the FDA's  review of our  NDA, the extent to  which the FDA  may 
request additional information or data and our ability to provide the same  in 
a timely manner, acceptability of the Phase 1, 2 and 3 clinical trial data  by 
the FDA,  FDA  approval of  the  Company's NDA  for  the treatment  of  ocular 
metastatic melanoma to the liver, adoption,  use and resulting sales, if  any, 
in the  United States,  adoption, use  and resulting  sales, if  any, for  the 
CHEMOSAT system to  deliver and filter  melphalan in the  EEA, our ability  to 
successfully commercialize the chemosaturation system and the potential of the
chemosaturation system as a treatment for patients with primary and metastatic
disease in the  liver, market acceptance  of the Gen  Two CHEMOSAT system  and 
patient  outcomes  using  the  same,   approval  of  the  current  or   future 
chemosaturation system for delivery  and filtration of melphalan,  doxorubicin 
or other chemotherapeutic agents for various  indications in the US and/or  in 
foreign markets, actions by the FDA or other foreign regulatory agencies,  our 
ability to  successfully enter  into  strategic partnership  and  distribution 
arrangements in foreign markets including Australia and key Asian markets  and 
timing an revenue, if any, of the same, the approval of the  Hepatic  CHEMOSAT 
Delivery System device to deliver and filter  doxorubicin in key Asian markets
and patient outcomes using the same,  our ability to obtain reimbursement  for 
the CHEMOSAT  system, uncertainties  relating  to the  timing and  results  of 
research and development  projects, uncertainties relating  to the timing  and 
results of future clinical trials, and uncertainties regarding our ability  to 
obtain financial  and  other  resources  for  any  research,  development  and 
commercialization activities. These  factors, and others,  are discussed  from 
time to time in our filings  with the Securities and Exchange Commission.  You 
should not place  undue reliance  on these  forward-looking statements,  which 
speak only  as of  the  date they  are made.  We  undertake no  obligation  to 
publicly update or revise these  forward-looking statements to reflect  events 
or circumstances after the date they are made.

Contact Information:
Investor Contact:           Media Contact:
Gregory Gin/Patty Eisenhaur Chris Gale
EVC Group                   EVC Group
646-445-4801/951-316-0577   646-201-5431

                                     ###

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Delcath Systems, Inc via Thomson Reuters ONE
HUG#1691404
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement